Cas:175136-19-3 3-[4-[(4-fluorophenyl)methoxy]phenyl]prop-2-enoic acid manufacturer & supplier

Chemical Name:3-[4-[(4-fluorophenyl)methoxy]phenyl]prop-2-enoic acid

CAS.NO:175136-19-3

Synonyms:3-[4-(4-Fluorobenzyloxy)phenyl]acrylicacid;4-(4-Fluorobenzyloxy)cinnamic acid

Molecular Formula:C₁₆H₁₃FO₃

Molecular Weight:272.27100

HS Code:2918990090

Physical and Chemical Properties:

Melting point:208-209ºC

Boiling point:452.9ºC at 760mmHg

Density:1.272g/cm3

Index of Refraction:1.617

PSA:46.53000

Exact Mass:272.08500

LogP:3.50250

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-[4-(4-Fluorobenzyloxy)phenyl]acrylicacid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(4-Fluorobenzyloxy)cinnamic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-[4-(4-Fluorobenzyloxy)phenyl]acrylicacid Use and application,3-[4-(4-Fluorobenzyloxy)phenyl]acrylicacid technical grade,usp/ep/jp grade.

Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 3-[4-[(4-fluorophenyl)methoxy]phenyl]prop-2-enoic acid manufacturer Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies. 3-[4-[(4-fluorophenyl)methoxy]phenyl]prop-2-enoic acid supplier In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. 3-[4-[(4-fluorophenyl)methoxy]phenyl]prop-2-enoic acid vendor Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. 3-[4-[(4-fluorophenyl)methoxy]phenyl]prop-2-enoic acid factory In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.